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Abstract
I describe here the history leading up to and including my laboratory's discovery of the first human
retrovirus, HTLV-I, and its close relative, HTLV-II. My efforts were inspired by early work showing
a retroviral etiology for leukemias in various animals, including non-human primates. My two main
approaches were to develop criteria for and methods for detection of viral reverse transcriptase
and to identify growth factors that could support the growth of hematopoietic cells. These efforts
finally yielded success following the discovery of IL-2 and its use to culture adult T cell lymphoma/
leukemia cells.
Background
After arriving at NIH in 1965 I spent my first year as a
young physician caring and treating (mostly unsuccess-
fully) acute leukemias in children: a vivid experience and
one which made me absolute in a decision to be fully
involved in laboratory research and not return to clinical
medicine. My research interest almost from the very start
was in the biology of blood cells, and I focused on com-
parisons of human leukemic cells with normal leukocytes.
This was mainly limited to comparative biochemistry.
Specifically, I studied enzymes of pyrimidine nucleoside
and nucleotide metabolism, tRNA species and their corre-
sponding amino acyl-tRNA synthetases, and finally DNA
polymerases [see refs.[1-5] as examples] – though now
this approach would seem to be empirical in the extreme,
because we have so many obvious rational things in can-
cer research today. However, at that time "fishing expedi-
tions" were "where things were at". I hoped to uncover
clues that might help us better understand the nature of
leukemic cells and also their origin.
Discovery that human T cells made cytokines 
("lymphokines") and early hints of human retroviruses
The main leukemia I worked on was acute lymphocytic
leukemias (ALL). After all, these were the most common
of the acute leukemias and gram quantities of these cells
were available from my clinical colleagues at NCI. Impor-
tantly, these were the only leukemias for which reasona-
bly similar normal control cells were available, namely,
normal human lymphoblasts. Scientists in Philadelphia
had just discovered that a plant lectin, phytohemaggluti-
nin (PHA), could induce human lymphocytes to become
activated and go through a mitotic cycle. These normal
lymphoblasts looked like ALL cells, but these were days
before most of us would or could know of the great com-
plexity of subtypes of lumphocytes. Functional discrimi-
natory assays were barely available and monoclonal
antibodies with their capacity to provide surface markers
were yet to come. Thus, we did not then sub-classify lym-
phocytic leukemias. Herb Cooper of NIH had learned
how to purify lymphocytes from columns packed with
nylon; myeloid cells would adhere, but lymphocytes
passed through. Cooper generously provided this
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technique to me. During this period (1968–1970) I
became very impressed by the studies of Leo Sachs in
Israel and later also of Don Metcalf in Australia who
where showing that, like some lymphocytes, myeloid cells
could also be grown in the laboratory but not in liquid
culture. Instead, they used the technique previously
applied to virus transformed cells of cell growth on a
methylcellulose solid surface in the form of cell colonies.
However, growth was transient and the amount of cells
quite limited, precluding many types of biochemical,
molecular biological, and virological experiments. None-
theless, from this system, Sachs and his colleagues and
Metcalf and co-workers made seminal discoveries, includ-
ing a growth/differentiation factor, granulocyte macro-
phage colony-stimulating factor (GM-CSF), which was
specific for the myeloid lineage. Sachs logically believed
the main production of GM-CSF would be from myeloid
cells, i.e., a feedback regulation – granulopoietic progeni-
tors proliferated and formed "dead end" granulocytes,
which should produce their own granulopoietic factor
[see refs. [6,7] for reviews].
Meanwhile, while comparing ALL cells to normal lym-
phocytes, I decided to test the conditioned medium of the
PHA-stimulated normal cells for growth factor. The late
Alan Wu had just joined me from the laboratories of Till
and McCulloch in Toronto shortly after the publication of
their famous paper describing hematopoietic stem cell
assays (in mice) for the first time. Alan and Joan Prival, a
post-doctoral fellow, joined me in reporting the then sur-
prising finding that lymphocytes (T cells) made GM-CSF
[8]. This would be the start of my long involvement with
"conditioned medium" from PHA-stimulated lym-
phocytes. Dane Boggs, F. Ruscetti, and co-workers in Pitts-
burgh had described the same phenomena at almost
exactly the same time. These papers were likely among the
first to describe lymphokines (lymphocyte-derived
cytokines).
In this period (early 1970s) I began to study animal retro-
viruses because in several animals these kinds of viruses
caused leukemias. Thus, no matter whether human retro-
viruses (leukemia-causing or otherwise) existed or not, a
study of animal retroviruses, especially focused on learn-
ing their mechanisms of leukemia causation, might pro-
vide insights into the mechanisms involved in human
leukemias. However, my co-workers and I also decided to
search for human retroviruses, an unpopular goal at this
time, considering the decades of attempts and failures. I
was, nonetheless, encouraged by discussions with Wil-
liam Jarrett, the Scottish veterinarian who discovered
feline leukemia virus, and by the work of the late Howard
Temin. Temin, of course, had predicted that retroviruses
of animals replicated by having their RNA genome tran-
scribed into a DNA form, which would then integrate into
the DNA of the target cell. He referred to this integrated
form as provirus, the name given to his theory. In 1970
Temin and his colleague Mizutani, and separately, David
Baltimore, gave credence to the theory with their discov-
ery of the DNA polymerase carried by all retroviruses,
reverse transcriptase (RT)[9,10]. For me it also meant a
convenient, inexpensive, and extremely sensitive assay for
a retrovirus. (This would be one of two technologies that
would be key for later discoveries of all human
retroviruses).
RT forms in virions only upon budding from the cell.
Consequently, finding this enzyme in media of cultured
cells implied release of retrovirus particles, and finding RT
from extracts of cells implied the presence of a cell associ-
ated virus particles, as for example, virions associated with
the cell surface membrane. We found rare cases of leuke-
mia that scored positive in RT assays. The problem, how-
ever, was that RT might be a product of a normal cellular
gene. We needed to develop the assay not only as a very
sensitive one but also one that would distinguish RT from
all of the then known cellular DNA polymerases (alpha,
beta, and gamma). This became a major objective [see
refs. [5] and [11-14] for examples].
Armed with these RT assays we did find a few cases of
adult lymphocytic leukemias with RT showing all the
characteristics of RT from a retrovirus (we had by then
purified and characterized RT from many different animal
retroviruses). We published on the one best characterized
in Nature New Biology in 1972 [15]. We believed this was
a "footprint" of a human retrovirus, but we failed to iso-
late virus from this patient. (Though we will never know,
it is interesting to speculate whether this young adult had
ATL because of some clinical similarities to ATL). We also
thought it would attract wide interest and excitement in
the field. It did not. It was clear that we had to isolate a
replicating virus, one we could study, perpetuate, and give
to others.
The obvious and easiest approach to virus isolation was
by using cell lines. Cell culture technology had become
widely available by the 1960s, and many cell lines from
different species were available. The approach is generally
to co-culture the primary cells (in our case the leukemic
cells) with a wide variety of such lines and hope virus will
take in one or more. This, of course, would be after scoring
positive in the RT assay. However, by this period, there
was increasing antagonism to research directed toward the
finding of human tumor viruses and especially of retrovi-
ruses. The NCI had created the heavily funded Virus Can-
cer Program which was under attack for failing to find
clear evidence of tumor viruses. Moreover, by the mid-
1970s there had been not only decades of failure to find
human retroviruses, there had been many false starts byRetrovirology 2005, 2:17 http://www.retrovirology.com/content/2/1/17
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many investigators utilizing the co-culture system that
involved cell lines, including one by me. The usual prob-
lem was a cross contamination with an animal retrovirus.
For this reason I became convinced that we had to find
ways to grow primary blood cells, but not with the sys-
tems of Sachs and Metcalf. These methylcellulose colonies
of leukocytes provided too few cells and growth of these
cells were limited in number and in time. When we had
our next hint of an RT positive leukemic sample it turned
out to be from a patient with a myeloid leukemia, so we
searched for a growth factor that would maintain and pro-
mote growth of human myeloid leukemic cells in liquid
suspension culture. This had not been achieved before.
From an early-term (first few weeks) abortion, we
obtained some human embryonic cells that produced a
factor that led to the first successful routine growth of
these human leukemic cells in liquid suspension(16). We
called these HL (human leukemia) cells, with a given
sequential number of the samples we had studied. One of
these cultured cell populations became an immortalized
cell line, HL-60. It was the first human leukemic myeloid
cell line [17] and like almost all the others, the HL-60 cells
showed no evidence of virus. However, one growing
human leukemic cell culture (not immortalized) did yield
virus, and it was anxiously propagated. Unfortunately, the
embryonic factor needed to keep these cells alive and
growing was lost when the freezer in which they were
stored broke down over a long holiday weekend, which
was not recognized for some time. (My first lesson in
never storing a divisible valuable all in one place!). This
led us to a frantic search to find another source. We
screened conditioned medium from a wide variety of cell
lines and cell strains, including many more fetal cells – all
to no avail.
One approach was to culture many different types of cells
from many different tissue sources (including human
embryos) for several days, collect the media (conditioned
media or CM), and add it to leukocytes from normal
human cord blood, samples of human bone marrow, and
myeloid leukemic cells. In this period (early mid-1970s),
a post-doctoral fellow, Doris Morgan, joined our group
and took part in the search. As would be expected, CM
from PHA-stimulated lymphocytes was one of the cell
sources I asked to be screened. Doris was succeeding in
growing cells from human bone marrow, and was
intensely nursing them daily for months. But they were
lymphocytes, not myeloid cells. It was neither unique nor
interesting to grow human B cells. Even at this time
Epstein-Barr virus (EBV) immortalized cell lines were well
known to grow often from normal blood or a bone mar-
row mixed cell population. Indeed, they were the only
kind of blood cells that could be routinely grown in long-
term culture, but analyses of the cells revealed that they
were T cells, which at that time had only recently been
clearly delineated from B cells by certain functional assays
(the E rosette assay, for example). The factor we had found
in the PHA-CM was a new growth factor. Francis Ruscetti
had then joined our group and carried out a set of experi-
ments that demonstrated this more fully, and we reported
these results in 1976–1977[18,19] and they were to be the
first reports of what we termed a T cell mitogenic factor,
later called TCGF, and finally interleukin-2 (IL-2). The
purification was later [20]. IL-2 was among the first well-
defined cytokines. The combination of IL-2 growth of T
cells with sensitive RT assays would be (and still is) the
key to the discoveries of human retroviruses in T cell
leukemias and AIDS.
The debate about the possible existence of human 
retroviruses
In this same period the pressure against attempts to find
human retroviruses intensified. It was not only the pre-
vailing atmosphere of failure but also reasonable scientific
arguments. For examples: (1) there was little evidence for
leukemia viruses in primates. (2) When retroviruses were
found in animals they were not difficult to find. Extensive
viremia preceded disease, therefore, if they infected
humans, they would be easy to find and would have been
discovered much earlier. (3) Human sera in the presence
of complement lysed animal retroviruses, thereby provid-
ing a rational mechanism for the conclusion that humans
were protected.
Finally, there were technical difficulties such as the ability
to culture primary human cells (see Table 1).
We reasoned otherwise. Kawakami and colleagues had
just discovered gibbon ape leukemia virus, and linked it to
chronic myeloid leukemia in that species [21]. Later, we
discovered a variant of that virus which caused T cell
leukemia [22]. Bovine leukemia virus (BLV) was discov-
Table 1: Factors that led to consensus that human retroviruses did not exist
1. Failure to discover them after an extensive survey by many investigators in the 1950s, 1960s, and 1970s.
2. Ease of detection in animal models because of extensive virema.
3. Difficulties in growing primary human cells.
4. Results showing human sera with complement lysed animal retroviruses.Retrovirology 2005, 2:17 http://www.retrovirology.com/content/2/1/17
Page 4 of 7
(page number not for citation purposes)
ered [23,24], and it was noted that BLV replicated at very
low levels thus putting to rest the notion of "extensive
viremia always precedes animal retrovirus induced leuke-
mias". The biased view came from the fact that the earlier
small animal models were naturally selected for their util-
ity. Consequently, models in which virus is difficult to
detect would be selected against. As for human sera lysing
retroviruses, unfortunately those studies were limited to
tests of retroviruses from non-primates. Later, we would
learn that many primate retroviruses, including the retro-
viruses of many, are not susceptible.
Our ultimate focus on T cell leukemias was dictated by
several factors. First, most animal leukemias caused by ret-
roviruses are lymphocytic leukemias and of these T cell
leukemias predominate. Second, the first and to this date
only leukemia of non-human primates is caused by a ret-
rovirus [21], and a particular strain of this virus which we
isolated caused T cell leukemia [22]. Third, fortune dic-
tated that we would end up focusing on human T cell
malignancies because of our discovery of IL-2 which
allowed us to grow significant numbers of such cells in
many but not all instances (not all T cell leukemias or
lymphomas respond to IL-2).
One other development also influenced our continuation
of the pursuit of human retroviruses. This was a docu-
mented interspecies transmission of a gibbon ape leuke-
mia virus (GaLV) from a pet old world Gibbon ape to a
new world Wooly monkey. It was well known that retro-
viruses could move from one species to another, but in all
cases these were very ancient events only discovered by
analyses of cellular DNA of many animals. But in this case
the event occurred "right before our eyes", giving rise to
the virus from the Wooly monkey known as simian sar-
coma virus [25]. We felt humans could not be excluded,
and indeed later we would learn that the first human ret-
rovirus discovered (HTLV-1) has close relatives among
many old world primates and may have arisen from an
ancient transmission from monkey to man. A more rele-
vant example, of course, is HIV. There is much evidence
that it came into humans as a much more recent infection
from African primates (see Table 2).
Discoveries of HTLV-1 and HTLV-2
The first detection and isolation of HTLV-1 was in 1979,
and the first detection came from the analysis of a T cell
line established by J. Minna and A. Gazdar from a patient
these clinicians called a cutaneous T cell lymphoma. Alter-
natively, such patients were also called mycosis fungoides
or Sezary T cell leukemia depending upon clinical
nuances. Though IL-2 was supplied by us for them to use
in their initial culturing of these cells, the cells rapidly
immortalized. An outstanding post-doctoral fellow, Ber-
nard Poiesz, carried out RT assays on these cells with pos-
itive results, and we soon arranged for electron
microscopic analysis of concentrated RT plus cultures and
found retrovirus particles. Because putative human retro-
viruses viruses had been found many times before by sev-
eral investigators in established cell lines, only to be
subsequently shown to be accidental laboratory contami-
nants, by the late 1970s I was well aware that much more
had to be done before this work was presentable. For
instance, we had to (1) show that the same virus could be
isolated from primary tissue samples of the same patient
by culturing primary T cells with IL-2; (2) demonstrate
that the virus was novel, i.e., not any of the known animal
retroviruses; (3) show it could infect human T cells in
vitro; (4) demonstrate specific antibodies to the virus in
the serum of the patient; (5) demonstrate that proviral
DNA could be found integrated in the DNA of the cells
from which the virus was isolated; (6) provide evidence
that this was not a one-time affair by showing serological
evidence of specific antibodies not only in the patient but
in others as well. These results were successfully obtained
in 1979–1980 and available by the time we submitted
and published our first report in 1980 [27], enabling us to
follow quickly with several other essential reports [28-33],
also including independent isolates from other patients
[29,34]. One of these patients was a black woman from
the Caribbean, and the second was a white merchant
marine who acknowledged sexual contacts in southern
Japan and the Caribbean. These and all subsequent iso-
lates of HTLV-1 in our laboratory were from primary cells
cultured with IL-2. After an initial struggle to publish in
the J. of Virology, fortunately, we were soon able to
publish the original report in PNAS, and this opened the
door. It soon became clear that HTLV-1 was specifically
associated with adult T cell malignancy (usually CD4+
Table 2: Factors encouraging us to continue searching for human retroviruses
1. The discovery of bovine leukemia virus (minimally replicates, difficult to find)
2. Technological advances – A. A sensitive specific assay for a footprint of a retrovirus, namely, reverse transcriptase. B. Capacity to grow significant 
numbers of primary human T cells in liquid suspension culture giving us access to virus detection and isolation, namely by using IL-2.
3. Discovery of a retrovirus causing leukemias in a species close to man, namely GaLV.
4. A documented example of a retrovirus transmission from one species of primates to another, namely GaLV from a gibbon ape to a wooly 
monkey [26].
5. Purification and characterization of reverse transcriptase from a patient with an adult lymphocytic leukemia (type unknown) 1972 [15].Retrovirology 2005, 2:17 http://www.retrovirology.com/content/2/1/17
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cells) in which the patients frequently had cutaneous
abnormalities and hypercalcemia. Clinicians in the
United States had not at that time made any distinction of
HTLV-1-associated T cell malignancies from other neo-
plasms, and as noted above collectively referred to these
patients with others (non-HTLV associated) as cutaneous
T cell leukemia-lyumphomas. However, a few years earlier
Kiyoshi Takatsuki and his co-workers Junji Yodoi and
Takashi Uchiyama defined clusters of leukemia in south-
west Japan with special clinical features and cellular mor-
phology, which when coupled with the geographic
clustering, led him to propose in 1977 that this was a dis-
tinct form of leukemia. He named it adult T cell leukemia
(ATL) [35].
Two events significantly catalyzed the further develop-
ment of our work and of our understanding of HTLV-1
and its role in T cell malignancies. The first of these (in the
summer of 1980) was information from Drs. Tom Wald-
mann and H. Uchiyama, who had come to NIH as a visit
scientist. They brought to our attention the ATL cluster in
Japan so in the fall of 1980 I contacted two Japanese
friends, the late Yohei Ito, then Chair of Microbiology at
Kyoto University and Tad Aoki for more information and
for sera from such patients to test for antibodies to HTLV.
This specific clinical entity had been described as early as
1977 by Takatsuki and his co-workers Yodoi and Uchi-
yama, and was called adult T cell leukemia by him. Aoki
and Ito sent sera from such patients to me in 1980, and
these sera scored positive for antibodies to HTLV-1. Based
on these results Ito organized a small meeting at Lake
Miwa outside of Kyoto attended by a few co-workers and
myself from the U.S. and Aoki, Ito, and several other Jap-
anese scientists most notably Takatsuki, Y. Hinuma, and
T. Miyoshi. The meeting was held in March 1981. Several
of my colleagues and I presented our results in detail. This
included description of several isolates of HTLV-1, charac-
teristics of purified HTLV-1 p24 as well as reverse tran-
scriptase proteins, evidence of integrated HTLV-1 provirus
T cell malignancies and healthy volunteers which pro-
vided clear evidence for the linkage of HTLV-1 to certain T
cell malignancies, and the positive serological results in
Japanese ATL patients. In organizing this meeting the
intention of Ito was to foster wide collaboration in Japan
with me and my co-workers on this disease. The meeting
summary was published in Cancer Research in November
1981 [36].
It was only at the end of the meeting when we were sum-
marizing and planning for this collaboration with the Jap-
anese investigators, that Dr. Yorio Hinuma "announced"
he too had a retrovirus. He presented EM pictures of virus
particles from a cell line established by Dr. Miyoshi by co-
cultivation of ATL cells and normal human T cells. These
results of Miyoshi were the first indication of the trans-
forming capability of HTLV-l because the cell line that was
immortalized was from the normal donor [37]. Later, my
colleague M. Popovic was able to make this a routine, that
is, we would show that HTLV-1 could routinely immortal-
ize normal human T cells [34]. It was obvious to all that
the virus pictures shown by Hinuma were HTLV-1. By the
time of this meeting we had already published a few
papers on HTLV-1. Hinuma called his isolate ATLV (adult
T cell leukemia virus), but argued against collaboration
claiming it was not possible to provide human sera from
Japan for "cultural reasons". In June 1982 Hinuma and
colleagues published on their isolate of ATLV [38]. After
comparative analyses of isolates of ATLV and HTLV were
performed we published with Japanese colleagues M.
Yoshida, T. Miyoshi and Y. Ito that HTLV-1 and ATLV were
the same virus [39]. Consequently, we agreed that the
virus name should be HTLV to recognize the priority of
our virus work, and the disease would be referred to as
ATL in recognition of the Japanese priority in distinguish-
ing this malignancy as a specific identity which had been
"lumped" with other T cell leukemias/lymphomas in
western countries and elsewhere as cutaneous T cell lym-
phomas [40]. Yoshida was soon to make many of the
major advances in the molecular biology of HTLV-1 but
this is another story.
The second meeting of considerable importance was in
London chaired by the late hematologist Sir John Dacie
and attended by Dacie, Drs. Daniel Catovsky, Robin
Weiss, Mel Greaves, and William Jarrett among others
from Great Britain and by my collaborator in epidemio-
logical studies, Dr. William Blattner, and myself. It was
Catvosky who called for this meeting because he noted
that we had found HTLV-1 mainly in African Americans
and black persons in the Caribbean and he had found an
unusual frequency of adult T cell malignancies in Carib-
bean immigrants to England. He recognized the similari-
ties of their disease to Takatsuki's ATL. Thus, he postulated
they were one and the same disease and HTLV-1 would be
present in all. He was right. Promptly, Blattner accelerated
his studies in the Caribbean and documented that HTLV-
1 was endemic in some islands. He and Guy de Thé of
France would then show that this result depended upon
the particular tribes in Africa from which the individuals
descended.
Some of these experiences would be a precursor of a per-
sistent pattern, i.e., HTLVs are not easy to transmit, remain
within families and regions over long periods of time, and
have old-world linkage. Ultimately, related viruses would
be found in old-world primates and more distantly
related viruses in some ungulates. The modes of
transmission would soon be forthcoming as sexual con-
tact, blood, and mother to child via breast feeding. Later
in 1981 we isolated HTLV-2 from a leukemia described asRetrovirology 2005, 2:17 http://www.retrovirology.com/content/2/1/17
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"a hairy cell T cell leukemia" [41], but this strain is far less
pathogenic that HTLV-1. Many of the features of these
viruses coupled with CD4 T cell tropism would prove to
be remarkably similar to those of the virus about to enter
our work, HIV.
A companion article in Retrovirology by Kiyoshi Takat-
suki recounts the events surrounding the discovery of the
disease, adult T-cell leukemia [41].
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